BlackRock, Inc. ownership in DUL / Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

DE ˙ XTRA ˙ US02043Q1076

251,80 € ↑6,70 (2,73%)

2026-06-03
AKTIENPREIS

Security	DE:DUL / Alnylam Pharmaceuticals, Inc.
Institution	BlackRock, Inc.
Latest Disclosed Ownership	8,546,557 shares
Ownership	6.80%

2024-01-26 - BlackRock, Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 8,546,557 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL). This represents 6.8 percent ownership of the company. In their previous filing dated 2023-01-31 , BlackRock, Inc. had reported owning 8,665,702 shares, indicating a decrease of -1.37 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2024-01-26	2024-01-26	13G/A	8,665,702	8,546,557	-1.37	6.80	-2.86
2023-01-31	2023-01-31	13G/A	7,671,402	8,665,702	12.96	7.00	9.37
2022-02-03	2022-02-03	13G/A	8,723,720	7,671,402	-12.06	6.40	-14.67
2021-01-29	2021-01-29	13G/A	8,723,720	8,723,720	0.00	7.50	0.00
2021-01-29	2021-01-29	13G/A	8,033,256	8,723,720	8.60	7.50	4.17
2020-02-05	2020-02-05	13G/A	6,145,805	8,033,256	30.71	7.20	18.03
2019-02-04	2019-02-04	13G/A	7,115,063	6,145,805	-13.62	6.10	-15.28
2018-02-08	2018-02-08	13G/A	4,386,945	7,115,063	62.19	7.20	41.18
2017-01-30	2017-01-30	13G	4,224,438	4,386,945	3.85	5.10	4.08
2016-12-09	2016-12-09	13G/A	4,290,930	4,224,438	-1.55	4.90	-3.92
2016-01-28	2016-01-28	13G		4,290,930		5.10
2014-07-10	2014-07-10	13G/A		3,097,404		4.10
2014-01-28	2014-01-28	13G/A		3,941,556		6.20
2013-02-06	2013-02-06	13G/A		3,298,120		6.29
2012-02-13	2012-02-13	13G/A		2,263,901		5.30

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	10,444,908	44,034	0.42	3,455,907	-16.44	0.0045
2026-02-12	2025-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	10,400,874	497,273	5.02	4,135,908	-8.42	0.0699
2025-11-12	2025-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,903,601	-76,562	-0.77	4,516,042	38.77	0.0791
2025-08-12	2025-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,980,163	420,781	4.40	3,254,431	26.08	0.0620
2025-05-02	2025-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,559,382	-325,875	-3.30	2,581,224	10.97	0.0542
2025-02-07	2024-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,885,257	177,839	1.83	2,326,100	-12.87	0.0471
2024-11-13	2024-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,707,418	159,755	1.67	2,669,831	15.07	0.0560
2024-08-13	2024-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,547,663	522,656	5.79	2,320,082	72.01	0.0525
2024-05-10	2024-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,025,007	503,892	5.91	1,348,787	-17.30	0.0314
2024-02-13	2023-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,521,115	128,111	1.53	1,631,027	9.73	0.0416
2023-11-13	2023-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,393,004	6,842	0.08	1,486,401	-6.68	0.0427
2023-08-11	2023-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,386,162	-162,800	-1.90	1,592,868	-6.99	0.0439
2023-05-12	2023-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,548,962	59,582	0.70	1,712,528	-15.12	0.0505
2023-02-13	2022-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,489,380	820,702	10.70	2,017,501	31.44	0.0632
2022-11-14	2022-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	7,668,678	6,003	0.08	1,534,961	37.34	0.0522
2022-08-12	2022-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	7,662,675	53,721	0.71	1,117,601	-10.05	0.0359
2022-05-12	2022-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	7,608,954	-62,448	-0.81	1,242,466	-4.49	0.0335
2022-02-10	2021-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	7,671,402	-1,249,570	-14.01	1,300,916	-22.77	0.0331
2021-11-09	2021-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,920,972	224,569	2.58	1,684,369	14.26	0.0472
2021-08-11	2021-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,696,403	-316,082	-3.51	1,474,214	15.85	0.0410
2021-05-07	2021-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,012,485	288,765	3.31	1,272,473	12.23	0.0374
2021-02-05	2020-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,723,720	-176,450	-1.98	1,133,822	-12.50	0.0362
2020-11-06	2020-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,900,170	-223,281	-2.45	1,295,865	-4.10	0.0478
2020-08-14	2020-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,123,451	550,598	6.42	1,351,274	44.81	0.0539
2020-05-01	2020-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,572,853	539,597	6.72	933,156	0.86	0.0456
2020-02-13	2019-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	8,033,256	928,087	13.06	925,189	61.92	0.0355
2019-11-08	2019-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	7,105,169	567,916	8.69	571,396	20.46	0.0240
2019-08-22	2019-06-30	13F/A-1	ALNYLAM PHARMACEUTICALS	COM	02043Q107	6,537,253	109,126	1.70	474,340	-21.04	0.0203
2019-08-13	2019-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	6,537,253	109,126		474,340
2019-05-09	2019-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	6,428,127	282,322	4.59	600,707	34.06	0.0268
2019-02-08	2018-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	6,145,805	61,777	1.02	448,089	-15.85	0.0226
2018-11-09	2018-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	6,084,028	-55,242	-0.90	532,474	-11.94	0.0230
2018-08-09	2018-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	6,139,270	-1,038,792	-14.47	604,654	-29.27	0.0279
2018-05-09	2018-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	7,178,062	62,999	0.89	854,909	-5.43	0.0409
2018-02-09	2017-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	7,115,063	1,003,366	16.42	903,969	25.89	0.0430
2017-11-14	2017-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	6,111,697	923,506	17.80	718,061	73.52	0.0362
2017-08-10	2017-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	5,188,191	441,957	9.31	413,811	70.12	0.0219
2017-05-12	2017-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	4,746,234	4,732,617	34,755.21	243,242	47,688.21	0.0134
2017-02-10	2016-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,617	-60,440	-81.61	509	-89.86	0.0007
2016-11-08	2016-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	74,057	-13,208	-15.14	5,020	3.65	0.0072
2016-08-10	2016-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	87,265	17,529	25.14	4,843	10.65	0.0073
2016-05-10	2016-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	69,736	15,965	29.69	4,377	-13.52	0.0070
2016-02-11	2015-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	53,771	21,003	64.10	5,061	92.14	0.0074
2015-11-13	2015-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	32,768	-15,115	-31.57	2,634	-54.11	0.0041
2015-08-07	2015-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	47,883	45,965	2,396.51	5,740	2,755.72	0.0085
2015-05-13	2015-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	1,918	82	4.47	201	12.92	0.0003
2015-02-09	2014-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	1,836	-51	-2.70	178	21.09	0.0003
2014-10-29	2014-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	1,887	51	2.78	147	26.72	0.0002
2014-08-06	2014-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	1,836	75	4.26	116	-1.69	0.0002
2014-05-02	2014-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	1,761	0	0.00	118	4.42	0.0002
2014-02-12	2013-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	1,761	-69,328	-97.52	113	-97.52	0.0002
2013-11-12	2013-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	71,089	-10,100	-12.44	4,550	80.84	0.0086
2013-08-13	2013-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	81,189	81,189		2,516		0.0050

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.